Fred Aslan, Artiva Biotherapeutics CEO

Arti­va boasts ear­ly NK cell ther­a­py re­sults, giv­ing life­line to part­ner Af­fimed

Arti­va Bio­ther­a­peu­tics re­port­ed ear­ly da­ta on its off-the-shelf NK cell ther­a­py in com­bi­na­tion with rit­ux­imab, sug­gest­ing the com­bo could shrink tu­mors in non-Hodgkin lym­phoma pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.